Contact
searchSearch
HMP Global

Interactive Features

Quiz
Ruxolitinib Combined With Novel Agents for the Treatment of MF
09/12/2025
True or False: According to results from the ADORE clinical trial, ruxolitinib combined with siremadlin treatment demonstrated the least promising safety and efficacy for patients with myelofibrosis, compared with other novel agents in...
True or False: According to results from the ADORE clinical trial, ruxolitinib combined with siremadlin treatment demonstrated the least promising safety and efficacy for patients with myelofibrosis, compared with other novel agents in...
True or False: According to...
09/12/2025
Oncology
Quiz
Allogeneic Stem Cell Transplantation for R/R CLL
09/11/2025
True or False: For patients with high-risk or R/R chronic lymphocytic leukemia, including those previously treated with pathway inhibitors, allogeneic hematopoietic stem cell transplantation demonstrated improved outcomes.
True or False: For patients with high-risk or R/R chronic lymphocytic leukemia, including those previously treated with pathway inhibitors, allogeneic hematopoietic stem cell transplantation demonstrated improved outcomes.
True or False: For patients with...
09/11/2025
Oncology
Quiz
Efficacy and Safety of Tazemetostat for R/R DLBCL and FL
08/25/2025
True or False: Based on results from a meta-analysis evaluating the safety and efficacy of tazemetostat among patients with R/R FL or DLBCL, the EZH2 inhibitor demonstrated promise as a viable treatment option, demonstrating meaningful...
True or False: Based on results from a meta-analysis evaluating the safety and efficacy of tazemetostat among patients with R/R FL or DLBCL, the EZH2 inhibitor demonstrated promise as a viable treatment option, demonstrating meaningful...
True or False: Based on results...
08/25/2025
Oncology
Quiz
Venetoclax and CPX-531 for R/R AML
08/25/2025
True or False: In a phase 1b/2 trial evaluating the efficacy and safety of venetoclax plus CPX-531 for the treatment of R/R acute myeloid leukemia, the combination therapy showed promising clinical activity, especially among patients in...
True or False: In a phase 1b/2 trial evaluating the efficacy and safety of venetoclax plus CPX-531 for the treatment of R/R acute myeloid leukemia, the combination therapy showed promising clinical activity, especially among patients in...
True or False: In a phase 1b/2...
08/25/2025
Oncology
Quiz
Ziftomenib Monotherapy for R/R NPM1-Mutant AML
08/13/2025
True or False: According to results from the phase 2 KOMET-001 trial, ziftomenib demonstrated promising efficacy and safety among patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.
True or False: According to results from the phase 2 KOMET-001 trial, ziftomenib demonstrated promising efficacy and safety among patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.
True or False: According to...
08/13/2025
Oncology
Quiz
Venetoclax Plus Bortezomib and Dexamethasone Therapy for R/R MM
08/04/2025
In the phase 3 BELLINI clinical trial, patients with R/R multiple myeloma who received venetoclax combined with bortezomib and dexamethasone demonstrated what median PFS compared to treatment with a placebo?
In the phase 3 BELLINI clinical trial, patients with R/R multiple myeloma who received venetoclax combined with bortezomib and dexamethasone demonstrated what median PFS compared to treatment with a placebo?
In the phase 3 BELLINI clinical...
08/04/2025
Oncology
Quiz
Olutasidenib for R/R IDH1-Mutant AML
07/17/2025
In the post hoc analysis evaluating olutasidenib for R/R IDH1-mutant AML, patients treated earlier in the treatment sequence (after 1 to 2 prior regimens) demonstrated which overall response rate?
In the post hoc analysis evaluating olutasidenib for R/R IDH1-mutant AML, patients treated earlier in the treatment sequence (after 1 to 2 prior regimens) demonstrated which overall response rate?
In the post hoc analysis...
07/17/2025
Oncology
Quiz
Belantamab Mafodotin Combination for R/R Multiple Myeloma
07/17/2025
In the DREAMM-8 trial, patients with multiple myeloma treated with belantamab mafodotin, pomalidomide, and dexamethasone demonstrated what median PFS compared to those receiving pomalidomide, bortezomib, and dexamethasone?
In the DREAMM-8 trial, patients with multiple myeloma treated with belantamab mafodotin, pomalidomide, and dexamethasone demonstrated what median PFS compared to those receiving pomalidomide, bortezomib, and dexamethasone?
In the DREAMM-8 trial, patients...
07/17/2025
Oncology
Quiz
Tislelizumab Plus HMA and CAG for Relapsed/Refractory AML
06/16/2025
In an expanded phase 2 trial evaluating the addition of tislelizumab to a HMA plus CAG chemotherapy regimen for patients with high-risk R/R acute myeloid leukemia, what was the reported overall response rate in the group treated with...
In an expanded phase 2 trial evaluating the addition of tislelizumab to a HMA plus CAG chemotherapy regimen for patients with high-risk R/R acute myeloid leukemia, what was the reported overall response rate in the group treated with...
In an expanded phase 2 trial...
06/16/2025
Oncology
Quiz
Triplet Regimen for Relapsed/Refractory Multiple Myeloma
06/16/2025
What was the most common grade ≥ 3 adverse event associated with a weekly triplet regimen of carfilzomib, cyclophosphamide, and dexamethasone for patients with relapsed/refractory multiple myeloma?
What was the most common grade ≥ 3 adverse event associated with a weekly triplet regimen of carfilzomib, cyclophosphamide, and dexamethasone for patients with relapsed/refractory multiple myeloma?
What was the most common grade ≥...
06/16/2025
Oncology

In the News

News
Ibrutinib Plus Chemoimmunotherapy Approved by European Commission for Patients With Previously Untreated MCL: TRIANGLE Trial
07/24/2025
Emily Estrada
The European Commission has approved ibrutinib combined with chemoimmunotherapy for the treatment of mantle cell lymphoma based on results from the phase 3 TRIANGLE clinical trial which demonstrated superior survival outcomes compared with...
The European Commission has approved ibrutinib combined with chemoimmunotherapy for the treatment of mantle cell lymphoma based on results from the phase 3 TRIANGLE clinical trial which demonstrated superior survival outcomes compared with...
The European Commission has...
07/24/2025
Oncology
News
AQUILA Phase 3 Trial Leads to European Commission Approval of Daratumumab for Smoldering Multiple Myeloma
07/24/2025
Emily Estrada
For patients with high-risk smoldering multiple myeloma, fixed-duration daratumumab has been approved by the European Commission based on results from the AQUILA phase 3 clinical trial.
For patients with high-risk smoldering multiple myeloma, fixed-duration daratumumab has been approved by the European Commission based on results from the AQUILA phase 3 clinical trial.
For patients with high-risk...
07/24/2025
Oncology
News
Patients With Acute Myeloid Leukemia and Concurrent DNMT3A and TET2 Mutations Demonstrate Lower Survival Outcomes
07/17/2025
Emily Estrada
Among elderly patients with AML, DNMT3A and TET2 mutations are associated with worse survival outcomes, while IDH1/IDH2 mutations are associated with improved survival, though these mutations were not found to significantly influence choice...
Among elderly patients with AML, DNMT3A and TET2 mutations are associated with worse survival outcomes, while IDH1/IDH2 mutations are associated with improved survival, though these mutations were not found to significantly influence choice...
Among elderly patients with AML,...
07/17/2025
Oncology
News
Pomalidomide-Based Regimen Shows Improved Overall Response Rate and Progression-Free Survival for Patients With MM in First Relapse
07/17/2025
Emily Estrada
A regimen of bortezomib and dexamethasone plus pomalidomide demonstrated superior survival outcomes and responses among patients with first-relapsed multiple myeloma, compared with bortezomib and dexamethasone alone.
A regimen of bortezomib and dexamethasone plus pomalidomide demonstrated superior survival outcomes and responses among patients with first-relapsed multiple myeloma, compared with bortezomib and dexamethasone alone.
A regimen of bortezomib and...
07/17/2025
Oncology
Conference Coverage
BET Inhibitor INCB057643 Shows Promising Efficacy for Treatment of Relapsed/Refractory Myelofibrosis
07/14/2025
Emily Estrada
The small-molecular BET inhibitor, INCB057643, demonstrated clinical activity and manageable safety among patients with relapsed/refractory myelofibrosis.
The small-molecular BET inhibitor, INCB057643, demonstrated clinical activity and manageable safety among patients with relapsed/refractory myelofibrosis.
The small-molecular BET...
07/14/2025
Oncology
Conference Coverage
Imetelstat Combined With Ruxolitinib Demonstrates Promising Activity for Patients With Myelofibrosis: IMproveMF Trial
07/14/2025
Emily Estrada
The combination of imetelstat plus ruxolitinib for patients with intermediate-1, intermediate-2, or high-risk myelofibrosis demonstrated manageable safety and promising activity, according to interim results from the IMproveMF trial.
The combination of imetelstat plus ruxolitinib for patients with intermediate-1, intermediate-2, or high-risk myelofibrosis demonstrated manageable safety and promising activity, according to interim results from the IMproveMF trial.
The combination of imetelstat...
07/14/2025
Oncology
News
Venetoclax and CPX-531 Demonstrates Promising Activity Among Patients With Relapsed/Refractory Acute Myeloid Leukemia
07/10/2025
Emily Estrada
The combination of venetoclax with CPX-351, a liposome of cytarabine and daunorubicin, demonstrated clinical activity among patients with relapsed/refractory acute myeloid leukemia, according to results from a phase 2 trial.
The combination of venetoclax with CPX-351, a liposome of cytarabine and daunorubicin, demonstrated clinical activity among patients with relapsed/refractory acute myeloid leukemia, according to results from a phase 2 trial.
The combination of venetoclax...
07/10/2025
Oncology
News
Venetoclax Plus Bortezomib and Dexamethasone Combination Therapy Demonstrates Inferior Overall Survival for Patients With R/R MM
07/09/2025
Emily Estrada
Venetoclax plus bortezomib and dexamethasone treatment demonstrated inferior overall survival and superior progression-free survival for patients with relapsed/refractory multiple myeloma compared to patients treated with placebo.
Venetoclax plus bortezomib and dexamethasone treatment demonstrated inferior overall survival and superior progression-free survival for patients with relapsed/refractory multiple myeloma compared to patients treated with placebo.
Venetoclax plus bortezomib and...
07/09/2025
Oncology
News
Quadruplet Regimen of Subcutaneous Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone Shows Efficacy for Newly Diagnosed MM
07/08/2025
Emily Estrada
A quadruplet therapy of subcutaneous daratumumab in addition to bortezomib, thalidomide, and dexamethasone demonstrated promising efficacy and safety among patients with newly diagnosed multiple myeloma.
A quadruplet therapy of subcutaneous daratumumab in addition to bortezomib, thalidomide, and dexamethasone demonstrated promising efficacy and safety among patients with newly diagnosed multiple myeloma.
A quadruplet therapy of...
07/08/2025
Oncology
FDA Approval
FDA Approves Linvoseltamab-gcpt for Patients With Relapsed/Refractory Multiple Myeloma
07/02/2025
Emily Estrada
The US FDA approved linvoseltamab-gcpt for the treatment of adults with relapsed/refractory multiple myeloma based on results from the LINKER-MM1 clinical trial.
The US FDA approved linvoseltamab-gcpt for the treatment of adults with relapsed/refractory multiple myeloma based on results from the LINKER-MM1 clinical trial.
The US FDA approved...
07/02/2025
Oncology

Latest Podcasts

Podcasts
Dr Leonard Shares Highlights to Expect at the 2020 Lymphoma, Leukemia & Myeloma Congress
10/19/2020
John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.
John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.
John Leonard, MD, discusses what...
10/19/2020
Oncology
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress
Podcasts
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress
08/24/2020
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an...
08/24/2020
Oncology
Podcasts
Seattle Children's Hospital Leukemia Program Offers Multidisciplinary Care to Underserved Population
06/19/2018
Todd Cooper, DO, discusses a new program launched at The Seattle Children's Hospital for patients with high-risk leukemia.
Todd Cooper, DO, discusses a new program launched at The Seattle Children's Hospital for patients with high-risk leukemia.
Todd Cooper, DO, discusses a new...
06/19/2018
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use